Document |
Document Title |
WO/2024/059317A1 |
Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
WO/2024/051819A1 |
A compound of general formula (I) or a stereoisomer, mesomer/racemate, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, an intermediate thereof, a preparation method therefor, and...
|
WO/2024/036112A1 |
Described herein are amide prodrugs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating a CNS disease or disorder.
|
WO/2024/025389A1 |
The present invention relates to a method for preparing a phthalazinone derivative, which is an inhibitor of Poly (ADP-ribose) polymerase (PARP), and a method for preparing an intermediate used in the preparation method and an acid addit...
|
WO/2024/019957A1 |
Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
|
WO/2024/020156A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
WO/2024/010782A1 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
|
WO/2024/008680A1 |
The present invention generally relates to compounds inhibiting dipeptidyl peptidase 1 activity; particularly the invention relates to compounds that are azetidine derivatives, including pharmaceutically acceptable salts thereof, methods...
|
WO/2024/006985A1 |
Described herein are fatty acid amide hydrolase (FAAH) cleavable prodrugs of compounds that modulate sphingosine- 1 -phosphate receptor 5 (S1P5), methods of making such compounds, pharmaceutical compositions and medicaments comprising su...
|
WO/2023/250197A2 |
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, st...
|
WO/2023/221952A1 |
Provided in the present application are a cyclic quaternary ammonium salt compound, and a preparation method therefor and the use thereof. Further provided are the cyclic quaternary ammonium salt compound as represented by general formul...
|
WO/2023/223055A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
|
WO/2023/218423A1 |
The invention features indazole-linked azetidine and indazole-linked methylethanamine compounds as small molecule 5-HT2 receptor ligands, and pharmaceutical compositions thereof, useful for treating 5-HT2 responsive conditions, such as a...
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
WO/2023/214119A1 |
The present disclosure relates to compounds of formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, wherein R1 to R9 are as defined in the claims. Further is disclosed compounds of formula (I) for use in the treat...
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
WO/2023/208170A1 |
Provided are a protease inhibitor, a method for preparing same, and use thereof. The protease inhibitor can be combined with one or more pharmaceutically acceptable excipients or one or more other active ingredients to be used as a PLpro...
|
WO/2023/208171A1 |
Disclosed in the present invention are a PLpro protease inhibitor, and a preparation method and application thereof. The PLpro protease inhibitor can be combined with one or more pharmaceutically acceptable auxiliary materials or one or ...
|
WO/2023/198904A1 |
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: (I), wherein R1 and R2 represent hydrogen or deuterium; R3 represents hydrogen, -COOH or -OH; R3' and R3" represent hydrogen, methyl...
|
WO/2023/198901A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof formula (I) wherein R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" independently represent a hydrogen atom, a methy...
|
WO/2023/198907A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof formula (I) wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3'...
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
WO/2023/196993A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present inven...
|
WO/2023/186881A1 |
The invention relates to p38 MAP kinase inhibitors of formula (I) as shown in the description for use in the treatment of colorectal cancer. Further, the invention relates to p38 MAP kinase inhibitors specifically mentioned in the descri...
|
WO/2023/182754A1 |
The present invention relates to an organic compound that can enhance the light efficiency of light extracted to the outside of an organic light-emitting element due to having a low refractive index, and thus can be effectively utilized ...
|
WO/2023/178107A2 |
Compounds, proteins, crosslinked proteins, compositions thereof, and methods of making and uses thereof. A compound, which may be an alpha-amino acid, comprises one or more beta-lactam group(s), one or more triazole groups, substituted a...
|
WO/2023/178283A1 |
The present disclosure relates generally to crystals, and more specifically to co-crystals of RRx-001 or 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods of preparing and using the co-crystals to treat or prevent various diseases...
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2023/160039A1 |
Disclosed in the present invention are a β-elemene derivative with an HDACi pharmacophore, and a preparation method therefor and the use thereof. Provided in the present invention are a β-elemene derivative with an HDACi pharmacophore ...
|
WO/2023/164201A1 |
A compound which is useful as a STING inhibitor is provided. The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory a...
|
WO/2023/164118A1 |
Compounds according to formula I: wherein Ar is an aryl or heteroaryl group, A is a C1-C3 alkyl, Z and Y are independently C1-C3 alkylene, X is C1-C3 alkylene, and R1-R5 are selected from -H, halogen, C1-C3 alkyl, or phenyl, or a pharmac...
|
WO/2023/160672A1 |
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
|
WO/2023/154480A1 |
Compositions and methods for preventing or treating a disease or a disorder associated with dyslipidemia are provided. This includes prevention or treatment of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatiti...
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
WO/2023/125182A1 |
A compound as represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof; an intermediate thereof and a preparation method there...
|
WO/2023/130023A1 |
Provided herein are 1 H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl methanone compounds substituted with aryl and pyrazolyl moieties, further substituted, for inhibiting rnonoacylglycerol lipase (MAGL), utilized in the treatment of a MAGL-m...
|
WO/2023/116774A1 |
A compound containing a bis(azanylylidene) sulfonyl structure of formula (I) as a PKR agonist and/or USP9X inhibitor, which can be used for treating related diseases mediated and regulated by PKR and USP9X, wherein the related diseases c...
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
WO/2023/110394A1 |
The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
|
WO/2023/107563A1 |
Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases. Formula (I).
|
WO/2023/088285A1 |
A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious...
|
WO/2023/072671A1 |
The present invention relates to the use of strobilurin type compounds of formula I and the N- oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b...
|
WO/2023/074847A1 |
The present invention provides: a novel spiro compound having a TRH-DE inhibition activity and useful for the prevention/treatment of various diseases associated with TRH and/or symptoms associated with the diseases, or a pharmacological...
|
WO/2023/077040A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
WO/2023/064493A1 |
This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
|
WO/2023/064225A1 |
Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or diso...
|
WO/2023/064343A1 |
Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical comp...
|